Medicare Enrolled
Dr. Robert March, MD
Hematology & Oncology · Nyack, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. March from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. March?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. March
Dr. Robert March is a hematology & oncology specialist in Nyack, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. March performed 1,868 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. March received a total of $17,241 from 89 pharmaceutical and/or device companies across 864 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. March is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 33% volume in NY
$17,241 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗1,868
Medicare services
Top 33% in NY for hematology & oncology
Not available
Unique patients (not deduplicated)
$104
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
909 | $85 | $537 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
759 | $111 | $381 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
123 | $159 | $746 |
| New patient office visit, complex (60-74 min) | 77 | $176 | $1,068 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$17,241
Total received (2018-2024)
Avg $2,463/year across 7 years
Top 19% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
89
Companies
864
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,122
2023
$2,830
2022
$1,677
2021
$651
2020
$1,350
2019
$3,594
2018
$4,018
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$250
PFIZER INC.
$245
ABBVIE INC.
$240
Gilead Sciences, Inc.
$194
Merck Sharp & Dohme LLC
$169
Mirati Therapeutics, Inc.
$150
Eisai Inc.
$111
Incyte Corporation
$105
Janssen Biotech, Inc.
$104
Takeda Pharmaceuticals U.S.A., Inc.
$103
Exelixis Inc.
$102
E.R. Squibb & Sons, L.L.C.
$100
ARRAY BIOPHARMA INC
$98
Alexion Pharmaceuticals, Inc.
$83
Celgene Corporation
$82
Blueprint Medicines Corporation
$73
Myriad Genetic Laboratories, Inc.
$70
Acrotech Biopharma Inc.
$70
Lilly USA, LLC
$68
TAIHO ONCOLOGY, INC.
$65
EMD Serono, Inc.
$61
Astellas Pharma US Inc
$61
AstraZeneca Pharmaceuticals LP
$58
Bayer Healthcare Pharmaceuticals Inc.
$56
Stemline Therapeutics Inc.
$46
Novocure Inc.
$41
JAZZ PHARMACEUTICALS INC.
$39
Kite Pharma, Inc.
$33
SHIELD THERAPEUTICS INC
$33
BeiGene USA, Inc.
$29
Ipsen Biopharmaceuticals, Inc
$28
Pharmacosmos Therapeutics Inc.
$28
Karyopharm Therapeutics Inc.
$27
GlaxoSmithKline, LLC.
$26
Deciphera Pharmaceuticals Inc.
$20
Kyowa Kirin, Inc.
$20
PUMA BIOTECHNOLOGY, INC.
$20
MorphoSys, US Inc.
$14
Top 3 companies account for 23.5% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,379
Janssen Biotech, Inc.
$1,178
Novartis Pharmaceuticals Corporation
$1,157
E.R. Squibb & Sons, L.L.C.
$958
PFIZER INC.
$954
AstraZeneca Pharmaceuticals LP
$883
Gilead Sciences, Inc.
$699
Genentech USA, Inc.
$570
Takeda Pharmaceuticals U.S.A., Inc.
$498
Pharmacyclics LLC, An AbbVie Company
$431
Incyte Corporation
$423
Merck Sharp & Dohme LLC
$401
Lilly USA, LLC
$394
Alexion Pharmaceuticals, Inc.
$383
Merck Sharp & Dohme Corporation
$366
Astellas Pharma US Inc
$335
ABBVIE INC.
$318
Exelixis Inc.
$298
Eisai Inc.
$289
Mirati Therapeutics, Inc.
$237
Seagen Inc.
$214
Celgene Corporation
$210
GENZYME CORPORATION
$187
Boehringer Ingelheim Pharmaceuticals, Inc.
$183
Regeneron Healthcare Solutions, Inc.
$179
Bayer HealthCare Pharmaceuticals Inc.
$176
Kyowa Kirin, Inc.
$175
EMD Serono, Inc.
$173
Bayer Healthcare Pharmaceuticals Inc.
$166
Janssen Pharmaceuticals, Inc
$160
Ipsen Biopharmaceuticals, Inc
$141
Teva Pharmaceuticals USA, Inc.
$140
TAIHO ONCOLOGY, INC.
$127
Blueprint Medicines Corporation
$121
Shire North American Group Inc
$108
Puma Biotechnology, Inc.
$106
Octapharma USA, Inc.
$103
AMAG Pharmaceuticals, Inc.
$102
SANOFI-AVENTIS U.S. LLC
$100
AbbVie Inc.
$100
EISAI INC.
$98
ARRAY BIOPHARMA INC
$98
Taiho Oncology, Inc.
$92
Acrotech Biopharma Inc.
$86
Kite Pharma, Inc.
$84
Welch Allyn
$79
Stemline Therapeutics Inc.
$75
SOBI, INC
$74
AbbVie, Inc.
$71
Myriad Genetic Laboratories, Inc.
$70
BeiGene USA, Inc.
$66
Karyopharm Therapeutics Inc.
$62
Coherus Biosciences Inc.
$56
TerSera Therapeutics LLC
$55
Helsinn Therapeutics (U.S.), Inc.
$52
Pharmacosmos Therapeutics Inc.
$51
Seattle Genetics, Inc.
$51
MorphoSys, US Inc.
$50
GlaxoSmithKline, LLC.
$46
Agios Pharmaceuticals, Inc.
$43
TESARO, Inc.
$43
CTI BioPharma Corp.
$42
Novocure Inc.
$41
Medtronic, Inc.
$40
JAZZ PHARMACEUTICALS INC.
$39
Pharmacyclics LLC, an AbbVie Company
$39
Global Blood Therapeutics, Inc.
$39
Jazz Pharmaceuticals Inc.
$38
Rigel Pharmaceuticals, Inc.
$38
SHIELD THERAPEUTICS INC
$33
Sirtex Medical Inc
$32
SERVIER PHARMACEUTICALS LLC
$24
Dova Pharmaceuticals
$24
ImmunoGen, Inc.
$22
Progenics Pharmaceuticals, Inc.
$21
Servier Pharmaceuticals LLC
$21
G1 Therapeutics, Inc.
$21
Deciphera Pharmaceuticals Inc.
$20
PharmaEssentia USA Corporation
$20
PUMA BIOTECHNOLOGY, INC.
$20
Daiichi Sankyo Inc.
$18
Clovis Oncology, Inc.
$18
Medtronic USA, Inc.
$18
Fortovia Therapeutics, Inc.
$17
Emmaus Medical, Inc.
$17
SECURA BIO, INC.
$16
PORTOLA PHARMACEUTICALS, LLC
$16
ADC Therapeutics America, Inc.
$15
Advanced Accelerator Applications
$9
Top 3 companies account for 21.5% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ADCETRIS · AFINITOR · AKYNZEO · ALUNBRIG · ANDEXXA · AYVAKIT · Alecensa · Aliqopa · Aranesp · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BOSULIF · BRUKINSA · Bavencio · CABOMETYX · CAMZYOS · COPIKTRA · COSELA · CUVITRU · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Elahere · Endari · Erleada · FARESTON · FASLODEX · FERAHEME · Fabhalta · GAZYVA · GILOTRIF · HYQVIA · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INVOKANA · IRESSA · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KYPHON Balloon Kyphoplasty · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYCHOICE CDX · MYRISK · NERLYNX · NINLARO · NUWIQ · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OXBRYTA · Onivyde · Optune · Orserdu · PADCEV · PIQRAY · POTELIGEO · PROMACTA · PYLARIFY · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · Soltamox · Stivarga · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TUKYSA · Tavalisse · Tazverik · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VELCADE · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · VYXEOS · Vectibix · Venclexta · Vonjo · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
483
County median income
$110,631
Nearest hospital to ZIP centroid (approximate)
NYACK HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. March is a clinical cardiology specialist, with moderate Medicare volume, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. March experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. March performed 909 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. March receive payments from pharmaceutical companies?
Yes. Dr. March received a total of $17,241 from 89 companies across 864 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. March's costs compare to other hematology & oncology specialists in Nyack?
Dr. March's average Medicare payment per service is $104. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. March) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Nyack
Browse hematology & oncology specialists in Nyack ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology